CAFE Comparison of Atypicals in First Episode of Psychosis

AstraZeneca

Status and phase

Completed

Phase 3

Conditions

Psychotic Disorders

Mental Disorders

Schizophrenia

Mental Health

Treatments

Drug: Olanzapine, risperidone

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00034892

5077IL/0114

Details and patient eligibility

About

The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.

Sex

All

Ages

16 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients must meet criteria for schizophreniform disorder, schizophrenia, or schizoaffective disorder with psychotic symptoms lasting 1-60 months
Psychotic symptoms must have persisted at least one month, and not more thn 5 years (60 months)
Patients must have no previous history of drug treatment (greater than a total of 16 weeks) with antipsychotics

Exclusion criteria

Patients with history of psychotic disorder with recovery period of at least 3 months
Female patients who are pregnant or nursing
Patients with a known history of mental retardation